Sleep and Cognition are Fundamentally Linked
A growing body of evidence underscores that sleep health and cognition are tightly interconnected. Longitudinal studies show that sleep disruption and short sleep duration can predict cognitive decline over time. In clinical trials, this relationship is actionable: sleep disorders can disrupt brain function in ways that are measurable with sensitive cognitive endpoints—and, importantly, those impairments may improve with effective treatment.
The Cogstate team of cognitive scientists and statisticians have the expertise to advise your team on vital study considerations, help you answer key drug development questions, and reduce risk and uncertainty in your trial. With access to thousands of cognitive data profiles—and from decades supporting drug development work—Cogstate can advise your team on endpoint selection, powering decisions, and interpretation of study results supportive of product efficacy, safety, and differentiating claims.
Case Example of Cogstate Sleep Disorder Solutions in Action
Development of New Digital Cognitive Test Supports Cognitive Measurement in Sleep-Related Program of Trials
A clinical study team at a large pharmaceutical company were developing a new wake-promoting compound and was interested in its potential impacts on cognition. They enlisted Cogstate to develop and implement a version of a gold-standard sleep measurement tool known as the Psychomotor Vigilance Test (PVT) within the Cogstate assessment system for use in their program. The high technical and timing precision of the Cogstate assessment system allowed the company to apply the PVT in their early development and late phase clinical trial programs. This also allowed them to leverage Cogstate distribution, training, quality assurance, and analyses systems. The Phase 2 study results were sufficient for the study team to continue to utilize the Cogstate PVT as key secondary outcome in their ongoing Phase 3 program of studies.
